Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/20/2010US20100125102 Estrogenic-active compounds and application thereof
05/20/2010US20100125101 Immunostimulatory nucleic acid molecules
05/20/2010US20100125100 GOLD NANOROD-siRNA COMPLEXES AND METHODS OF USING SAME
05/20/2010US20100125099 Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene
05/20/2010US20100125098 Treatment of cancer with complex organic-inorganic pigment compositions
05/20/2010US20100125097 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
05/20/2010US20100125096 Acetam Derivatives for Pain Relief
05/20/2010US20100125094 Pyrrolidinyl modulators of nicotinic acetylcholine receptors
05/20/2010US20100125093 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
05/20/2010US20100125092 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
05/20/2010US20100125091 Substituted heterocyclic compounds as ion channel modulators
05/20/2010US20100125090 Modulators of ATP-Binding Cassette Transporters
05/20/2010US20100125087 New compounds 575
05/20/2010US20100125086 Use of isoqc inhibitors
05/20/2010US20100125085 Pyridoindole modulators of nmda receptor and acetylcholinesterase
05/20/2010US20100125084 Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
05/20/2010US20100125082 New compounds 578
05/20/2010US20100125081 New compounds 574
05/20/2010US20100125080 Compounds for inflammation and immune-related uses
05/20/2010US20100125079 Biphenyl compounds useful as muscarinic receptor antagonists
05/20/2010US20100125078 Quinazoline derivatives as nk3 receptor antagonists
05/20/2010US20100125077 Polymorphs of Brimonidine Pamoate
05/20/2010US20100125076 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use
05/20/2010US20100125075 Antibacterial Agents
05/20/2010US20100125074 Thieno-[2,3-d]Pyrimidine and Thieno-Pyridazine Compounds and Methods of Use
05/20/2010US20100125073 Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
05/20/2010US20100125072 Spiro-oxindole compounds and their uses as therapeutic agents
05/20/2010US20100125071 Cxc-chemokine receptor ligands
05/20/2010US20100125070 Bupropion Metabolites and Methods of Their Synthesis and Use
05/20/2010US20100125069 Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
05/20/2010US20100125068 Methods for inhibiting protein kinases
05/20/2010US20100125067 Sulfonamide inhibitors of carbonic anhydrase ii
05/20/2010US20100125066 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
05/20/2010US20100125065 Carboline derivatives useful in the inhibition of angiogenesis
05/20/2010US20100125064 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases
05/20/2010US20100125063 Combinations of nicotinic acetylcholine alpha 7 receptor agonists
05/20/2010US20100125062 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
05/20/2010US20100125061 Naphthylacetic acids
05/20/2010US20100125060 Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
05/20/2010US20100125059 1-biarylazetidinone derivative
05/20/2010US20100125058 Naphthylacetic acids
05/20/2010US20100125057 Topical skin care composition
05/20/2010US20100125051 Parenteral Formulations Comprising Sugar-Based Esters and Ethers
05/20/2010US20100124576 Topical Treatment Formulation of Natural Ingredients for Enhancing Sexual Response
05/20/2010US20100124572 Magnetic microsphere and method of forming a microsphere
05/20/2010US20100124571 Use of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles
05/20/2010US20100124565 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
05/20/2010US20100124560 Multi portion intra-oral dosage form and use thereof
05/20/2010US20100124554 Redox-active compounds and related compounds, compositions, methods and systems
05/20/2010US20100124550 Amide inhibitors of renin
05/20/2010US20100124548 Pharmaceutical product
05/20/2010US20100124547 Compositions and methods for inhibiting expression of factor vii genes
05/20/2010US20100124545 Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
05/20/2010US20100124544 Crystalline forms of dihydropyrazolopyrimidinone
05/20/2010US20100124543 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
05/20/2010US20100124542 Amine dendrimers
05/20/2010US20100124541 Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
05/20/2010US20100124537 Medical applications of alpha-ketoglutarate
05/20/2010US20100122918 Ophthalmic and contact lens solution
05/20/2010DE102008057867A1 Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten Fat emulsion for parenteral nutrition of critically ill ICU patients
05/20/2010DE102008057364A1 New pyridyl or phenyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy
05/20/2010DE102008057344A1 Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung Aminoalkyl-substituted aryl compounds, and their use
05/20/2010DE102008057343A1 New phenyl or pyridyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy
05/20/2010DE102008057335A1 Intermediate, useful e.g. as an immunomodulator, for inhibiting the proliferation of certain hematopoietic tumor cells and stimulating erythropoiesis, comprises amorphous lenalidomide and a surface stabilizer
05/20/2010DE102008057285A1 New intermediate comprising lenalidomide and matrix material, in the form of a solid solution, useful e.g. as immunomodulatory drug, to inhibit proliferation of hematopoietic tumor cells and promote T-cell and natural killer cell immunity
05/20/2010DE102008057284A1 Preparation of tablets containing lenalidomide and adhesion promoter, where the tablets are produced by dry granulation or direct compression, useful e.g. for stimulating erythropoiesis and as an immunomodulator
05/20/2010DE102008056875A1 Arzneimittelformulierungen zur Behandlung von Lungenerkrankungen bei Frühgeborenen Pharmaceutical formulations for the treatment of lung disease of prematurity
05/20/2010CA2780624A1 Isoprenyl compounds and methods thereof
05/20/2010CA2745451A1 Compositions and methods for the treatment of altered a-synuclein function
05/20/2010CA2743938A1 Substituted isoindoles as bace inhibitors and their use
05/20/2010CA2743904A1 Cancer vaccine compositions and methods of using the same
05/20/2010CA2743902A1 Substituted dioxopiperidinyl phthalimide derivatives
05/20/2010CA2743861A1 Methods and compositions related to targeting monoacylglycerol lipase
05/20/2010CA2743749A1 Haloalkyl containing compounds as cysteine protease inhibitors
05/20/2010CA2743717A1 Azaquinolinone derivatives and uses thereof
05/20/2010CA2743709A1 Treatment of proteinopathies using a farnesyl transferase inhibitor
05/20/2010CA2743661A1 Aryl di-substituted propenone compounds
05/20/2010CA2743642A1 Therapies for hematologic malignancies
05/20/2010CA2743639A1 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
05/20/2010CA2743624A1 Chitosan derivatives to treat animals or optimize animal health
05/20/2010CA2743618A1 Two types of crystalline of pinocembrin, their preparation and their use for manufacture of pharmaceutical compositions
05/20/2010CA2743615A1 Compositions and methods for alleviating hyposalivation and for providing oral comfort
05/20/2010CA2743585A1 Chitosan derivatives alone or in combination for the treatment of mdr microbial infections
05/20/2010CA2743558A1 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
05/20/2010CA2743537A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010CA2743531A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/20/2010CA2743493A1 Surface modification of polymers via surface active and reactive end groups
05/20/2010CA2743491A1 Inhibition of mammalian target of rapamycin
05/20/2010CA2743489A1 Substituted bicyclic amines for the treatment of diabetes
05/20/2010CA2743487A1 Cd37 immunotherapeutic combination therapies and uses thereof
05/20/2010CA2743483A1 Tetrasubstituted pyridazine hedgehog pathway antagonists
05/20/2010CA2743464A1 Therapeutic and diagnostic methods relating to cancer stem cells
05/20/2010CA2743449A1 Pyrazinopyrazines and derivatives as kinase inhibitors
05/20/2010CA2743434A1 A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis
05/20/2010CA2743426A1 New crystal form of sunitinib malate
05/20/2010CA2743419A1 Antimicrobial compositions
05/20/2010CA2743403A1 Pyrimidinium derivatives for use in the treatment or prevention of diabetes
05/20/2010CA2743329A1 Antisense compositions and methods of making and using same
05/20/2010CA2743296A1 Appetite suppressing weight management composition comprising caralluma fimbriata, hoodia gordonii and cissus quadrangularis extracts
05/20/2010CA2743295A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy
1 ... 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 ... 7860